Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Transplantation. 2002 Oct 27;74(8):1190-2.

Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases.

Author information

  • 1Department of Pharmacy, Besançon University Hospital, Boulevard Fleming, 25030 Besançon Cedex, France.



Hemorrhagic cystitis (HC) is an important cause of morbidity in patients undergoing allogeneic stem-cell transplantation (SCT). Various causes have been identified, such as the use of high-dose cyclophosphamide or busulfan and the occurrence of acute graft-versus-host disease or viral infections (cytomegalovirus, adenovirus, polyomavirus).


The clinical course of four patients treated with factor XIII (FXIII) concentrate for severe HC after allogeneic SCT is described.


Four patients were treated with one or two infusions of 50 IU/kg of FXIII concentrate. Only one patient showed a plasmatic FXIII decrease before treatment. Three of the four patients responded to this treatment, and HC completely resolved in two of them. No adverse event was observed.


The use of FXIII concentrate can improve the major symptoms of HC in patients with decreased or normal FXIII plasma level after allogeneic SCT.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk